Molecular Templates faces delisting from Nasdaq due to non-compliance and plans to suspend trading on December 26, 2024.Quiver AI SummaryMolecular Templates, Inc., a clinical-stage biopharmaceutical company...
Molecular Templates received Nasdaq deficiency notices for late filings and failing to maintain minimum bid price.Quiver AI SummaryMolecular Templates, Inc. has received a notification from Nasdaq indicating...
June S&P 500 futures (ESM23) are down -0.21%, and June Nasdaq 100 E-Mini futures (NQM23) are down -0.34% this morning as market participants assessed recent labor market data while awaiting the release...
AUSTIN, Texas, May 17, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...
AUSTIN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...
Presentations from multiple pipeline programs feature clinical and preclinical data demonstrating the unique biology of Molecular Templates’ technology...
Event will feature a presentation by David Spigel, MD, chief scientific officer of the Sarah Cannon Research Institute Wednesday, April 13th @ 8:00 am...
AUSTIN, Texas, March 28, 2022 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage...